Headache
FDA accepts resubmission of NDA for Axsome’s oral migraine treatment
The FDA has accepted the resubmission of a new drug application for a novel, oral therapeutic intended to treat individuals with acute migraine, according to the manufacturer.
Real-world data confirm benefits of ravulizumab for atypical hemolytic uremic syndrome
Adults and children with atypical hemolytic uremic syndrome who switched from eculizumab to ravulizumab had stable renal function and hematologic values with similar safety seen in clinical trials, according to data from a registry study.
Monoclonal antibody superior to placebo in reducing migraine frequency
In patients with difficult-to-treat migraine, IV infusion of a novel monoclonal antibody provided superior migraine frequency relief compared with placebo in as early as 4 weeks, data show.
Ubrogepant may stop migraine before headache onset
Prodromal treatment with 100 mg ubrogepant was associated with greater functionality, fewer activity limitations and a high degree of satisfaction at 24 hours in patients with migraine, according to research published in Neurology.
OASIS: Nonhormonal elinzanetant improves hot flashes, menopause-related quality of life
Once-daily oral elinzanetant was well tolerated and improved moderate to severe vasomotor symptom frequency and severity, sleep disturbances and menopause-related quality of life, according to results of two studies published in JAMA.